Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Ranibizumab for Pterygium
NCT02342392Phase 3Completed
- Sponsor
- Universiti Sains Malaysia
- Start
- Sep 2012
- Primary completion
- Sep 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in pterygium (2 arms), sponsored by Universiti Sains Malaysia. Primary endpoint: Pterygium Recurrence Rate at 1 year. Started Sep 2012; status: completed.
02
Drugs
ranibizumab
03
Conditions
pterygium
Beyond the preview
Go deeper on NCT02342392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342392.